• Je něco špatně v tomto záznamu ?

Adjuvant therapy of histopathological risk factors of retinoblastoma in Europe: A survey by the European Retinoblastoma Group (EURbG)

S. Dittner-Moormann, M. Reschke, FCH. Abbink, I. Aerts, HT. Atalay, N. Fedorovna Bobrova, E. Biewald, IB. Brecht, S. Caspi, N. Cassoux, G. Castela, Y. Diarra, C. Duncan, M. Ebinger, D. Garcia Aldana, D. Hadjistilianou, T. Kepák, A. Klett, H....

. 2021 ; 68 (6) : e28963. [pub] 20210315

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22004286

INTRODUCTION: Advanced intraocular retinoblastoma can be cured by enucleation, but spread of retinoblastoma cells beyond the natural limits of the eye is related to a high mortality. Adjuvant therapy after enucleation has been shown to prevent metastasis in children with risk factors for extraocular retinoblastoma. However, histological criteria and adjuvant treatment regimens vary and there is no unifying consensus on the optimal choice of treatment. METHOD: Data on guidelines for adjuvant treatment in European retinoblastoma referral centres were collected in an online survey among all members of the European Retinoblastoma Group (EURbG) network. Extended information was gathered via personal email communication. RESULTS: Data were collected from 26 centres in 17 countries. Guidelines for adjuvant treatment were in place at 92.3% of retinoblastoma centres. There was a consensus on indication for and intensity of adjuvant treatment among more than 80% of all centres. The majority of centres use no adjuvant treatment for isolated focal choroidal invasion or prelaminar optic nerve invasion. Patients with massive choroidal invasion or postlaminar optic nerve invasion receive adjuvant chemotherapy, while microscopic invasion of the resection margin of the optic nerve or extension through the sclera are treated with combined chemo- and radiotherapy. CONCLUSION: Indications and adjuvant treatment regimens in European retinoblastoma referral centres are similar but not uniform. Further biomarkers in addition to histopathological risk factors could improve treatment stratification. The high consensus in European centres is an excellent foundation for a common European study with prospective validation of new biomarkers.

Amsterdam UMC Location VU University Medical Centre Amsterdam The Netherlands

Birmingham Children's Hospital Birmingham England

Centre for Pediatric Oncology and Hematology Vilnius University Vilnius Lithuania

Centro Hospitalar e Universitário de Coimbra University of Coimbra Coimbra Portugal

Charles University Prague 2nd Faculty of Medicine and University Hospital Motol Prague Czech Republic

Children's Hospital University of Tuebingen Tuebingen Germany

Department of Ophthalmology Amsterdam UMC Vrije Universiteit Amsterdam Cancer Center Amsterdam Amsterdam The Netherlands

Department of Ophthalmology Semmelweis University Budapest Hungary

Department of Ophthalmology University Duisburg Essen University Hospital Essen Essen Germany

Department of Particle Therapy University Hospital Essen West German Proton Therapy Centre Essen Essen Germany

Department of Pediatric Hematology and Oncology University Duisburg Essen University Hospital Essen Essen Germany

Department of Pediatric Hematology and Oncology University Hospital CHUV University of Lausanne Lausanne Switzerland

Department of Pediatric Hematology Oncology IRCCS Ospedale Pediatrico Bambino Gesù Rome Italy

Department of Pediatric Oncology and Hematology Charité Universitätsmedizin Berlin Berlin Germany

Department of Pediatric Oncology and Hematology University Children's Hospital of Krakow Krakow Poland

Division of Pediatric Hematology Oncology Medical University of Graz Graz Austria

East Tallinn Central Hospital Tallinn Estonia

Filatov Eye Institute Odessa Odessa Ukraine

Gazi University School of Medicine Ankara Turkey

German Consortium for Translational Cancer Research Heidelberg Germany

Hacettepe University Hospital Ankara Turkey

Hospital La Paz Madrid Spain

Hospital Sant Joan de Deu Barcelona Spain

Hospital Virgen Macarena Sevilla Spain

Institut Curie PSL Research University and University of Paris Paris France

Jules Gonin Eye Hospital Fondation Asile des Aveugles University of Lausanne Lausanne Switzerland

Ocular Oncology Siena University Hospital Siena Italy

Pediatric Hematology and Oncology University Hospital Vall d'Hebron Barcelona Spain

Pediatric Hematology Oncology and Stem Cell Transplant Division Padua University Hospital Padua Italy

Pediatric Oncology Sheba Medical Center Tel Aviv University Tel Aviv Israel

Royal London Hospital and Great Ormond Street Hospital London England

The Children's Memorial Health Institute Warsaw Poland

The Goldschleger eye institute Sheba Medical Center Tel Aviv University Tel Aviv Israel

University Hospital Brno and St Anna University Hospital ICRC Masaryk University Brno Czech Republic

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22004286
003      
CZ-PrNML
005      
20220127145357.0
007      
ta
008      
220113s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/pbc.28963 $2 doi
035    __
$a (PubMed)33720495
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Dittner-Moormann, Sabine $u Department of Pediatric Hematology and Oncology, University Duisburg-Essen, University Hospital Essen, Essen, Germany
245    10
$a Adjuvant therapy of histopathological risk factors of retinoblastoma in Europe: A survey by the European Retinoblastoma Group (EURbG) / $c S. Dittner-Moormann, M. Reschke, FCH. Abbink, I. Aerts, HT. Atalay, N. Fedorovna Bobrova, E. Biewald, IB. Brecht, S. Caspi, N. Cassoux, G. Castela, Y. Diarra, C. Duncan, M. Ebinger, D. Garcia Aldana, D. Hadjistilianou, T. Kepák, A. Klett, H. Kiratli, E. Maka, E. Opocher, K. Pawinska-Wasikowska, J. Rascon, I. Russo, O. Rutynowska-Pronicka, C. Sábado Álvarez, SSR. Pacheco, K. Svojgr, B. Timmermann, V. Vishnevskia-Dai, A. Eggert, P. Ritter-Sovinz, NE. Bechrakis, H. Jenkinson, A. Moll, FL. Munier, MB. Popovic, G. Chantada, F. Doz, P. Ketteler
520    9_
$a INTRODUCTION: Advanced intraocular retinoblastoma can be cured by enucleation, but spread of retinoblastoma cells beyond the natural limits of the eye is related to a high mortality. Adjuvant therapy after enucleation has been shown to prevent metastasis in children with risk factors for extraocular retinoblastoma. However, histological criteria and adjuvant treatment regimens vary and there is no unifying consensus on the optimal choice of treatment. METHOD: Data on guidelines for adjuvant treatment in European retinoblastoma referral centres were collected in an online survey among all members of the European Retinoblastoma Group (EURbG) network. Extended information was gathered via personal email communication. RESULTS: Data were collected from 26 centres in 17 countries. Guidelines for adjuvant treatment were in place at 92.3% of retinoblastoma centres. There was a consensus on indication for and intensity of adjuvant treatment among more than 80% of all centres. The majority of centres use no adjuvant treatment for isolated focal choroidal invasion or prelaminar optic nerve invasion. Patients with massive choroidal invasion or postlaminar optic nerve invasion receive adjuvant chemotherapy, while microscopic invasion of the resection margin of the optic nerve or extension through the sclera are treated with combined chemo- and radiotherapy. CONCLUSION: Indications and adjuvant treatment regimens in European retinoblastoma referral centres are similar but not uniform. Further biomarkers in addition to histopathological risk factors could improve treatment stratification. The high consensus in European centres is an excellent foundation for a common European study with prospective validation of new biomarkers.
650    _2
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
650    _2
$a adjuvantní chemoterapie $x metody $7 D017024
650    _2
$a dítě $7 D002648
650    _2
$a předškolní dítě $7 D002675
650    _2
$a kombinovaná terapie $x metody $7 D003131
650    _2
$a enukleace oka $7 D015353
650    _2
$a lidé $7 D006801
650    _2
$a prognóza $7 D011379
650    _2
$a adjuvantní radioterapie $x metody $7 D018714
650    _2
$a nádory sítnice $x patologie $x terapie $7 D019572
650    _2
$a retinoblastom $x patologie $x terapie $7 D012175
650    _2
$a rizikové faktory $7 D012307
650    _2
$a průzkumy a dotazníky $7 D011795
651    _2
$a Evropa $7 D005060
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Reschke, Madlen $u Department of Pediatric Oncology and Hematology, Charité - Universitätsmedizin Berlin, Berlin, Germany
700    1_
$a Abbink, Floor C H $u Amsterdam UMC, Location VU University Medical Centre, Amsterdam, The Netherlands
700    1_
$a Aerts, Isabelle $u Institut Curie, PSL Research University and University of Paris, Paris, France
700    1_
$a Atalay, Hatice Tuba $u Gazi University School of Medicine, Ankara, Turkey
700    1_
$a Fedorovna Bobrova, Nadezhda $u Filatov Eye Institute Odessa, Odessa, Ukraine
700    1_
$a Biewald, Eva $u Department of Ophthalmology, University Duisburg-Essen, University Hospital Essen, Essen, Germany
700    1_
$a Brecht, Ines B $u Children's Hospital, University of Tuebingen, Tuebingen, Germany
700    1_
$a Caspi, Shani $u Pediatric Oncology, Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel
700    1_
$a Cassoux, Nathalie $u Institut Curie, PSL Research University and University of Paris, Paris, France
700    1_
$a Castela, Guilherme $u Centro Hospitalar e Universitário de Coimbra, University of Coimbra, Coimbra, Portugal
700    1_
$a Diarra, Yelena $u Department of Pediatric Hematology and Oncology, University Duisburg-Essen, University Hospital Essen, Essen, Germany
700    1_
$a Duncan, Catriona $u Royal London Hospital and Great Ormond Street Hospital, London, England
700    1_
$a Ebinger, Martin $u Children's Hospital, University of Tuebingen, Tuebingen, Germany
700    1_
$a Garcia Aldana, David $u Hospital Virgen Macarena, Sevilla, Spain
700    1_
$a Hadjistilianou, Doris $u Ocular Oncology, Siena University Hospital, Siena, Italy
700    1_
$a Kepák, Tomáš $u University Hospital Brno and St. Anna University Hospital/ICRC, Masaryk University, Brno, Czech Republic
700    1_
$a Klett, Artur $u East-Tallinn Central Hospital, Tallinn, Estonia
700    1_
$a Kiratli, Hayyam $u Hacettepe University Hospital, Ankara, Turkey
700    1_
$a Maka, Erika $u Department of Ophthalmology, Semmelweis University, Budapest, Hungary
700    1_
$a Opocher, Enrico $u Royal London Hospital and Great Ormond Street Hospital, London, England $u Pediatric Hematology, Oncology and Stem Cell Transplant Division, Padua University Hospital, Padua, Italy
700    1_
$a Pawinska-Wasikowska, Katarzyna $u Department of Pediatric Oncology and Hematology, University Children's Hospital of Krakow, Krakow, Poland
700    1_
$a Rascon, Jelena $u Centre for Pediatric Oncology and Hematology, Vilnius University, Vilnius, Lithuania
700    1_
$a Russo, Ida $u Department of Pediatric Hematology/Oncology, IRCCS, Ospedale Pediatrico Bambino Gesù, Rome, Italy
700    1_
$a Rutynowska-Pronicka, Olga $u The Children's Memorial Health Institute, Warsaw, Poland
700    1_
$a Sábado Álvarez, Constantino $u Pediatric Hematology and Oncology, University Hospital Vall d'Hebron, Barcelona, Spain
700    1_
$a Pacheco, Sonsoles San Roman $u Hospital La Paz, Madrid, Spain
700    1_
$a Svojgr, Karel $u Charles University in Prague, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic
700    1_
$a Timmermann, Beate $u Department of Particle Therapy, University Hospital Essen, West German Proton Therapy Centre Essen (WPE), West German Cancer Center (WTZ), Essen, Germany $u German Consortium for Translational Cancer Research (DKTK), Essen, Germany German Cancer Research Center (DKFZ), Heidelberg, Germany
700    1_
$a Vishnevskia-Dai, Vicktoria $u The Goldschleger eye institute, Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel
700    1_
$a Eggert, Angelika $u Department of Pediatric Oncology and Hematology, Charité - Universitätsmedizin Berlin, Berlin, Germany
700    1_
$a Ritter-Sovinz, Petra $u Division of Pediatric Hematology/Oncology, Medical University of Graz, Graz, Austria
700    1_
$a Bechrakis, Nikolaos E $u Department of Ophthalmology, University Duisburg-Essen, University Hospital Essen, Essen, Germany
700    1_
$a Jenkinson, Helen $u Birmingham Children's Hospital, Birmingham, England
700    1_
$a Moll, Annette $u Department of Ophthalmology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands
700    1_
$a Munier, Francis L $u Jules-Gonin Eye Hospital, Fondation Asile des Aveugles, University of Lausanne, Lausanne, Switzerland
700    1_
$a Popovic, Maja Beck $u Department of Pediatric Hematology and Oncology, University Hospital CHUV, University of Lausanne, Lausanne, Switzerland
700    1_
$a Chantada, Guillermo $u Hospital Sant Joan de Deu, Barcelona, Spain
700    1_
$a Doz, François $u Institut Curie, PSL Research University and University of Paris, Paris, France
700    1_
$a Ketteler, Petra $u Department of Pediatric Hematology and Oncology, University Duisburg-Essen, University Hospital Essen, Essen, Germany $u German Consortium for Translational Cancer Research (DKTK), Essen, Germany German Cancer Research Center (DKFZ), Heidelberg, Germany
773    0_
$w MED00181047 $t Pediatric blood & cancer $x 1545-5017 $g Roč. 68, č. 6 (2021), s. e28963
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33720495 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220113 $b ABA008
991    __
$a 20220127145353 $b ABA008
999    __
$a ok $b bmc $g 1751682 $s 1155435
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 68 $c 6 $d e28963 $e 20210315 $i 1545-5017 $m Pediatric blood & cancer $n Pediatr Blood Cancer $x MED00181047
LZP    __
$a Pubmed-20220113

Najít záznam

Citační ukazatele

Možnosti archivace